MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer

Azani, Alireza; Omran, Sima Parvizi; Ghasrsaz, Haniyeh; Idani, Asra; Eliaderani, Mahdis kadkhodaei; Peirovi, Niloufar; Dokhani, Negar; Lotfalizadeh, Mohamad hassan; Rezaei, Mohammadhadi mohammadzadeh; Ghahfarokhi, Mehrnoosh shahgholian; KarkonShayan, Sepideh; Hanjani, Parisa najari; Kardaan, Zahra; Navashenagh, Jamshid Gholizadeh; Yousefi, Meysam; Abdolahi, Mitra; Salmaninejad, Arash

doi:10.1016/j.prp.2023.154618

Cited by 7 publications

(2 citation statements)

References 269 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97 In addition, CSC are resistant to apoptosis post treatment and OV-expressing apoptosis inducer TRAIL can significantly kill the CSCs in vitro and in the GBM xenografted mouse model. 98,99 Oncolytic vaccinia virus lacking the small subunit of ribonucleotide reductase, F4L gene, more efficiently infect and lysis the ALDH + CD44 + CD24+ CSCs. 100 Also, OV expressing moieties targeting of CD133, EpCAM, and HER2 can further enhance tumor specificity 101 (Table 4 and Figure 2C).…”

Section: Ovs Modulate Stemness Factormentioning

confidence: 99%

Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

Soroush,

Shahhosseini,

Ghavamikia

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

The heterogeneity of the solid tumor microenvironment (TME) impairs the therapeutic efficacy of standard therapies and also reduces the infiltration of antitumor immune cells, all of which lead to tumor progression and invasion. In addition, self‐renewing cancer stem cells (CSCs) support tumor dormancy, drug resistance, and recurrence, all of which might pose challenges to the eradication of malignant tumor masses with current therapies. Natural forms of oncolytic viruses (OVs) or engineered OVs are known for their potential to directly target and kill tumor cells or indirectly eradicate tumor cells by involving antitumor immune responses, including enhancement of infiltrating antitumor immune cells, induction of immunogenic cell death, and reprogramming of cold TME to an immune‐sensitive hot state. More importantly, OVs can target stemness factors that promote tumor progression, which subsequently enhances the efficacy of immunotherapies targeting solid tumors, particularly the CSC subpopulation. Herein, we describe the role of CSCs in tumor heterogeneity and resistance and then highlight the potential and remaining challenges of immunotherapies targeting CSCs. We then review the potential of OVs to improve tumor immunogenicity and target CSCs and finally summarize the challenges within the therapeutic application of OVs in preclinical and clinical trials.

show abstract

Section: Ovs Modulate Stemness Factormentioning

confidence: 99%

Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

Soroush,

Shahhosseini,

Ghavamikia

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…(ICV) = 77.57 increases the likelihood of serious adverse outcomes. Before prescribing alprazolam and during treatment, assess the risk of abuse and addiction in each patient(24)(25)(26)(27).…”

mentioning

confidence: 99%

The Effect of N-acetylcysteine on Alprazolam Withdrawal Symptoms in Wistar Male Albino Rats

Marvast,

Amnieh,

Navabazam

et al. 2024

CJMS

View full text Add to dashboard Cite

Introduction: Alprazolam is a benzodiazepine drug that is mainly used to treat generalized anxiety disorder and sleep disorders. Doctors' insistence on prescribing alprazolam due to its long half-life (16 hours) can lead to severe withdrawal complications. The aim of this study was to evaluate the effect of N-acetylcysteine (NAC) as an antioxidant drug on reducing the withdrawal symptoms of alprazolam in male albino rats. Material and Methods: In this experimental study, 50 albino male Wistar rats were used. 10 rats received normal saline by gavage for 26 days (sham), the rest of the rats received 1 mg / kg of alprazolam daily for 21 days and after drug dependence were randomly divided into 4 groups were divided. The negative control group received normal saline by gavage daily for up to 4 days after the dependence period. The treated groups also received 100, 200, and 400 mg / kg NAC orally for 4 days after the dependence period, after which the anti-anxiety and restless effects of N-acetylcysteine were assessed by behavioral test (Elevated plus-maze test). Results: The variables OAE (p = 0.18), CAE (p = 0.88), CAT (p = 0.53) and OAT percent (p = 0.29) did not show a significant difference between the 5 treatment groups; But OAT (p = 0.07) and OAE_percent (p = 0.001) showed a significant difference between the 5 treatment groups (p <0.05). Conclusion: Due to the antioxidant properties of NAC and its ability to counteract oxidative stress in the nervous system, it can be used to control the symptoms of withdrawal syndrome in people with a history of alprazolam dependence. In the present study, a dose of 400 mg / kg NAC had the best therapeutic effects in rats. In future studies, it is recommended to obtain an appropriate dose for people who experience symptoms of alprazolam withdrawal syndrome.

show abstract

An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls

Salmaninejad,

Layeghi,

Falakian

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) represent one of the most abundant tumor-infiltrating stromal cells, and their normal function in tumor microenvironment (TME) is to suppress tumor cells by producing cytokines which trigger both direct cell cytotoxicity and antibody-mediated immune response. However, upon prolonged exposure to TME, the classical function of these so-called M1-type TAMs can be converted to another type, “M2-type,” which are recruited by tumor cells so that they promote tumor growth and metastasis. This is the reason why the accumulation of TAMs in TME is correlated with poor prognosis in cancer patients. Both M1- and M2-types have high degree of plasticity, and M2-type cells can be reprogrammed to M1-type for therapeutic purposes. This characteristic introduces TAMs as promising target for developing novel cancer treatments. In addition, inhibition of M2-type cells and blocking their recruitment in TME, as well as their depletion by inducing apoptosis, are other approaches for effective immunotherapy of cancer. In this review, we summarize the potential of TAMs to be targeted for cancer immunotherapy and provide an up-to-date about novel strategies for targeting TAMs.

show abstract

MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer

Cited by 7 publications

References 269 publications

Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells

The Effect of N-acetylcysteine on Alprazolam Withdrawal Symptoms in Wistar Male Albino Rats

An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls

Contact Info

Product

Resources

About